Analytical instruments company Thermo Fisher Scientific Inc. /zigman2/quotes/201150432/composite TMO +2.25% reported Wednesday first-quarter profit and revenue that topped expectations, as revenue beats in its laboratory products, specialty diagnostics and life sciences segments offset a miss in analytical instruments. Net income fell to $788 million, or $1.97 a share, from $815 million, or $2.02 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share rose to $2.94 from $2.81, above the FactSet consensus of $2.80. Revenue grew 2% to $6.23 billion, above the FactSet consensus of $6.17 billion. The company announced last month a deal to buy diagnostics company Qiagen N.V. /zigman2/quotes/204869908/composite QGEN +2.52% for $11.5 billion. "We're clearly living in unprecedented times, and the COVID-19 pandemic has put a spotlight on the importance of the work we do at Thermo Fisher Scientific," said Chief Executive Marc Casper. "Our leading scale and depth of capabilities are key advantages in navigating this environment, and we were pleased to deliver a very good first quarter." The stock, which was still inactive in premarket trading, has lost 6.0% over the past three months, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.34% has shed 17.6%.